Plasmocure™ is a second-line anti-mycoplasma reagent. It is recommended for the elimination of mycoplasma that appear to be Plasmocin™ -resistant [1].

Plasmocure™ combines two antibiotics that act through different mechanisms than those found in Plasmocin™:
– the first antibiotic binds to the 50S subunit of the ribosome and blocks peptidyltransferase activity
– the second antibiotic binds to isoleucyl-tRNA synthetase and halts isoleucine incorporation into mycoplasma proteins.

A two-week treatment with Plasmocure™ is usually sufficient to completely eliminate mycoplasma. If mycoplasma elimination is not completed after two weeks, Plasmocure™ can be administered for an additional week. A moderate slowdown of cell growth may be observed, but full recovery of the cell line is expected once mycoplasma are eliminated.
One 1 ml vial is sufficient to treat 1 to 3.3 liters of culture.

Important: InvivoGen's anti-mycoplasma products are suitable for research purposes only, and not for human or animal care.